Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Saphris

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
OBJECTIVE To assess clinical features of therapeutic efficacy and tolerability of asenapine (saphris) in stopping acute psychotic… Expand
Is this relevant?
Review
2015
Review
2015
The causes and origins of pica remain unknown and are the source of speculation and heated debate. Bariatric surgery patients are… Expand
Is this relevant?
2013
2013
To the Editor: Asenapine, marketed as Saphris, is a relatively new psychopharmaceutical agent approved in 2009 for the treatment… Expand
Is this relevant?
Review
2011
Review
2011
Asenapine was approved by the Food and Drug Administration (FDA) in 2009. This article reviews clinically significant aspects of… Expand
Is this relevant?
2011
2011
T he US health system is under reform. More than ever, busy practitioners need help in prescribing drugs more knowledgeably and… Expand
Is this relevant?
2011
2011
FDA has issued a Safety Announcement warning that serious allergic reactions have been reported with the use of the antipsychotic… Expand
Is this relevant?
2010
2010
On August 14th, 2009, for the first time, the FDA has approved a psychotropic medication for two indications simultaneously… Expand
Is this relevant?
2010
2010
  • JAAPA : official journal of the American Academy…
  • 2010
  • Corpus ID: 11751591
 
Is this relevant?
2010
2010
Antipsychotic agents Asenapine (Saphris—Schering) and iloperidone (Fanapt—Vanda) are new atypical antipsychotic agents that join… Expand
Is this relevant?
2009
2009
The U.S. Food and Drug Administration has approved Saphris tablets to treat adults with schizophrenia, and bipolar I disorder in… Expand
Is this relevant?